The Next Frontier of Diabetic Foot Disease Treatment.
TRV-01 is a low-cost, non-invasive, scalable solution for outpatient care. If approved, it will be the ONLY therapeutic solution that CURES diabetic foot disease at the source.
.svg)
The Challenge
Diabetic foot disease is a serious complication of diabetes that affects millions worldwide. High blood sugar levels damage nerves and blood vessels in the feet, leading to chronic wounds, infections, and, in severe cases, amputations.
Current treatments focus on managing symptoms rather than addressing the underlying causes, resulting in stagnant healing rates of just 40% over the past 50 years. These prolonged treatments often lead to repeated clinic visits, financial strain, and a significant reduction in quality of life for patients, highlighting the urgent need for more effective solutions.
Our Solution
Triovance’s genetically engineered skin substitute, TRV-01, is a novel skin graft genetically engineered to accelerate the wound healing process in patients with diabetic foot disease.
By continuously secreting human insulin and VEGF in the wound bed, it promotes tissue regeneration and new blood vessel formation to accelerate wound healing while providing an impermeable barrier to prevent infections and further tissue damage. With a simplified application process and fewer visits to the hospital, our solution aims to improve patient adherence to treatment and enhance overall quality of life.
An Innovative Solution to Cure Diabetic Foot Disease From Within: TRV-01
How it works
- TRV-01 is an off-white sheet of approximately 44cm2 consisting of a viable, tissue-engineered epidermal allograft derived from keratinocytes grown on bovine collagen type I scaffold that can be applied directly to diabetic foot ulcers.
- The TRV-01 manufacturing process allows the differentiation of karatinocyte cells into a stratified, semi-permeable, full thickness epidermis (basal, spinous, granular and corneum) designed as a temporary wound cover and protective barrier.
- TRV-01's basal layer is genetically modified using a replicative incompetent adenoviral vector to continuously produce secreted insulin and vascular endothelial growth factor-A (VEGF-A).
- Insulin and VEGF act synergistically when secreted into the wound bed. Together, when delivered directly to a woundbed, these factors:
- Reduce advanced glycation end products (AGEs) that impair growth factor receptor function in the wound microenvironment.
- Improve cellular function by increasing proliferation and migration of endogenous keratinocytes and fibroblasts that mediate wound closure and healing.
- Enhance vascular network formation through increased angiogenesis to increase blood supply and improve oxygenation, accelerating healing.
- Restore the microenvironment of the wound by improving the regulation of inflammatory cytokines, which help counteract inflammation.
What Makes
TRV-01 Different from Current Treatments?
Differentiating Technology Features
.svg)
01
Full thickness epidermis skin graft.
02
Genetically engineered to secrete insulin and VEGF.
03
Gene therapy is localized to the skin graft.
Pipeline
Stay up to date on the status of all our treatments
currently in development.
